Dosing schedules of selected biologic RA therapies



[a]May also be administered 400 mg initially and at Weeks 2 and 4, followed by 200 mg every other week.

Please see respective prescribing information for dosing considerations for each product. All trademarks are the property of their respective owners. Data derived from full prescribing information for Rituxan,[1] Remicade,[2] Orencia,[3] Simponi,[4] Cimzia,[5] Humira,[6] and Enbrel.[7]

- Subsequent courses of Rituxan should be administered every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks.

Rituxan (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

The use of Rituxan in patients with RA who have not had prior inadequate response to one or more TNF antagonists is not recommended.

*Please see accompanying full prescribing information including **Boxed Warnings**.*

Rituxan®
Rituximab

INDICATION

Rituxan (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

IMPORTANT SAFETY INFORMATION

- Rituxan has been associated with **fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions and progressive multifocal leukoencephalopathy (PML)**
- Hepatitis B reactivation and cardiac arrhythmias and angina have also been observed
- Patients should be closely observed for signs of infection if biologic agents and/or DMARDs other than methotrexate are used concomitantly
- Common adverse reactions include infusion reactions and infections

Please see accompanying full prescribing information including ***Boxed Warnings*** *for additional safety information.*

References: 1. Rituxan [package insert]. South San Francisco, CA: Biogen Idec, Inc. and Genentech USA, Inc.; October 2009. **2.** Remicade [package insert]. Malvern, PA: Centocor, Inc.; 2006. **3.** Orencia [package insert]. Princeton, NJ: Bristol-Meyers Squibb Company; 2007. **4.** Simponi [package insert]. Horsham, PA; Centocor Ortho Biotech Inc.; 2009. 5. Cimzia [package insert]. Smyrna, GA: UCB; 2009. **6.** Humira [package insert]. North Chicago, IL: Abbott Laboratories; 2007.**7.** Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation; 2006.

Rituxan®
Rituximab

Genentech | biogen idec